GM-CSF

GM-CSF

GM-CSF 詳細

Molecule Name
Macrophage colony stimulating factor 2
分子の別称
GM-CSF,CSF2,MGC131935
Drug Development Progress
治験薬の数9
市販薬剤の数0
研究&開発段階NDA/BLA
ターゲットの別称
GM-CSF,Molgramostin,CSF2,Colony Stimulating Factor 2,Sargramostim,GMCSF,CSF,Granulocyte Macrophage-Colony Stimulating Factor,Granulocyte-Macrophage Colony Stimulating Factor,Colony-Stimulating Factor,Granulocyte-Macrophage Colony-Stimulating Factor,Colony Stimulating Factor 2 (Granulocyte-Macrophage),Molgramostim
バックグランド
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is also known as Colony stimulating factor 2 (granulocyte-macrophage), is a cytokine initially characterized by its ability to induce colonies of granulocytes and macrophages from myeloid progenitor cells, and is secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts. GM-CSF is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exitthe circulation and migrate into tissue, whereupon they mature into macrophages and dendritic cells. Thus, it is part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of the protein is found extracellularly as a homodimer. Human GM-CSF glycosylated in its mature form. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients. The preliminary results have been promising. GM-CSF is also used as a medication to stimulate the production of white blood cells following chemotherapy.

GM-CSF 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
OtilimabMOR-04357; GSK-3196165; GSK-165; MOR-103Phase 3 ClinicalUniversity Of Melbourne
Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Multiple Sclerosis; Osteoarthritis; Severe Acute Respiratory Syndrome; Spondylarthritis; Stomach Neoplasms
詳細
PlonmarlimabTJM-2; TJ-003234; TJ-003234RAR101Phase 3 ClinicalI-Mab Biopharma Co Ltd
Arthritis, Gouty; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome
詳細
Gemogenovatucel-TIND-14205Phase 3 ClinicalGradalis Inc
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma, Ewing; Uterine Cervical Neoplasms; Uterine Neoplasms
詳細
PBI-1402PBI-1402Phase 2 ClinicalPrometic Life Sciences
Anemia
詳細
Pexastimogene devacirepvecTG-6006; JX-594Phase 2 ClinicalNational Cancer Institute, Regeneron Pharmaceuticals Inc, Samsung Medical Center & Samsung Electronics Devices Llc, Sillajen Inc
Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Ovarian Neoplasms; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Wilms Tumor
詳細
Breast cancer therapy (BriaCell Therapeutics)Phase 2 ClinicalBriacell Therapeutics Corp
Breast Neoplasms; Metastatic breast cancer
詳細
GimsilumabMORAb-022; KIN-1901Phase 2 ClinicalMorphotek Inc
Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Inflammation; Rheumatic Diseases
詳細
MEDI-5395MEDI-5395; MEDI5395Phase 1 ClinicalMedimmune
Solid tumours
詳細
BBM-C101Phase 1 ClinicalBelief BioMed Inc
Squamous Intraepithelial Lesions of the Cervix
詳細